A Comparative Study of IV Ferric Carboxymaltose Versus Iron Sucrose in Treatment of Iron Deficiency Anemia in Pregnancy

Abstract

Background: To compare Intravenous Iron Sucrose Compound (ISC) with intravenous Ferric Carboxymaltose (FCM) in terms of efficacy as well as safety for treating iron deficient anaemia in pregnant patients. A novel IV iron preparation called ferric carboxymaltose was authorised by the Food and Drug Administration (FDA) in 2013 as an iron therapy substitute for adult patients with iron deficiency anaemia who are unable to tolerate oral iron or who do not respond well to it.

Objective: To evaluate the safety and effectiveness of ferric carboxymaltose (FCM) infusion against intravenous iron sucrose complex (ISC) injection in treating iron deficient anaemia in pregnancy.

Method: This current retrospective study was conducted among individuals with mild to severe iron-deficiency anaemia who are resistive to iron taken by mouth at Department of gynacology ,KIMS. There were 100 samples obtained in all. Any significant or mild adverse effects were recorded, and iron dextrose and ferric carboxymaltose were given to patients in accordance with guidelines. After using the appropriate statistical tests, a p value of less than 0.05 was deemed as statistically significant.

Results: In group FCM, the typical age of the patients was 31.48±7.151 years, whereas in group IS, it was 29.51±9.451 years. For groups FCM and IS, the beginning characteristics and clinical profiles appeared comparable (p<0.05).

Conclusion: In this trial, patients in the ferric carboxymaltose group behaved more quickly and much better to treatments than those in the iron-containing sucrose group, and this response was also linked to fewer side effects.